Delcath Q2 Revenue Beats by 11%, Raises 2026 Guidance to $104M-$108M
DCTH sits 79% above its 52-week low of $8.12.
Summary
Delcath Systems reported Q2 revenue of $29.13M, beating the $26.26M consensus by 11%, with net income flat year-over-year at $2.67M. The company raised its full-year 2026 revenue guidance to $104M-$108M, up from prior expectations, and now anticipates positive adjusted EBITDA for the year. HEPZATO volume grew approximately 30% year-over-year, driven by treatment center expansion and physician adoption. This follows a Q1 that showed strong revenue growth but a net loss; the Q2 profit and raised outlook signal accelerating commercial traction. With the stock trading near its 52-week high, the guidance raise and margin targets (86%-89% gross margin) provide concrete upside catalysts.
At the time of this announcement, DCTH was trading at $14.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $436M. The 52-week trading range was $8.12 to $13.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.